Loading stock data…
ABBV
$206.60-4.72 (-2.23%)
Market ClosedLast close May 1
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
AbbVie Inc. in the Healthcare sector is trading at $206.60. The stock is currently 16% below its 52-week high of $244.81, remaining 3.8% below its 200-day moving average. Technical signals show neutral RSI of 52 and bullish MACD crossover, explaining why ABBV maintains its current current market pressure. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 52) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$206.60
Potential Downside
106%
Whystock Fair Value$-12.30
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus30 analysts
Buy
Mean target$249.27+20.7%
Range$184.00 – $294.00
Fundamentals
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$354.64B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
84.24
Beta
Defensive asset. Lower volatility than the S&P 500.
0.36
Div Yield
Strong income play. Yield provides a meaningful total return floor.
337.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-115.08%
Volume
Today's trading volume
5.34M
Recent News
Discover 3 Stocks That Might Be Trading Below Estimated Value
In the last week, the United States market has stayed flat, although it is up 29% over the past year with earnings forecasted to grow by 16% annually. In such a climate, identifying stocks that might be trading below their estimated value can offer potential opportunities for investors seeking to capitalize on future growth.
Is AbbVie Inc. (ABBV) One of the Best Drug Stocks to Buy According to Analysts?
AbbVie Inc. (NYSE:ABBV) is one of the best drug stocks to buy according to analysts. AbbVie Inc. (NYSE:ABBV) announced on April 27 the submission of an application to the U.S. Food and Drug Administration (FDA) seeking approval for SKYRIZI® for subcutaneous induction for the treatment of adult patients with moderately to severely active Crohn’s disease. Management […]
Bank of America Upgrades AbbVie (ABBV) on Skyrizi Strength, Lifts PT
AbbVie Inc. (NYSE:ABBV) is included among the 10 Best Large Cap Dividend Growth Stocks to Invest in. On April 30, Bank of America analyst Tim Anderson upgraded AbbVie Inc. (NYSE:ABBV) to Buy from Neutral. It also lifted the price target on the stock to $234 from $226. The firm believes concerns around competitive erosion in […]
AbbVie Expected to Post Durable Growth Into Mid-2030s, BofA Securities Says
AbbVie (ABBV) is seen maintaining durable growth into the mid-2030s as investor concerns on competit
Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy
Our AbbVie (NYSE:ABBV) call lands on the constructive side of the ledger after a noisy but encouraging Q1 earnings report. The 24/7 Wall St. price target for AbbVie is $229.32, implying 12.47% upside from the recent close of $203.89. We rate ABBV a buy with high confidence (90%), driven by Skyrizi and Rinvoq momentum, raised ... Price Prediction: Why AbbVie’s Post-Humira Pivot Makes It a Strong Buy